Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: mas jl. N Engl J Med. 2006 Apr 20;354(16):1706-17. doi: 10.1056/NEJMoa060989. Epub 2006 Mar 12. N Engl J Med. 2006. PMID: 16531616 Free article. Clinical Trial.
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: mas jl. Am Heart J. 2005 Sep;150(3):401. doi: 10.1016/j.ahj.2005.03.017. Am Heart J. 2005. PMID: 16169314 Clinical Trial.
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.
Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. Ohman EM, et al. Among authors: mas jl. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004. Am Heart J. 2006. PMID: 16569533
REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year.
Sabouret P, Cacoub P, Dallongeville J, Krempf M, Mas JL, Pinel JF, Priollet P, Steg G, Taminau D, Montalescot G; REACH Registry investigators. Sabouret P, et al. Among authors: mas jl. Arch Cardiovasc Dis. 2008 Feb;101(2):81-8. doi: 10.1016/s1875-2136(08)70263-8. Arch Cardiovasc Dis. 2008. PMID: 18398391 Free article.
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Cerebrovasc Dis. 2009. PMID: 19372653 Free article. Clinical Trial.
Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease.
Mechtouff L, Touzé E, Steg PG, Ohman EM, Goto S, Hirsch AT, Röther J, Aichner FT, Weimar C, Bhatt DL, Alberts MJ, Mas JL; REACH Registry Investigators. Mechtouff L, et al. Among authors: mas jl. J Intern Med. 2010 Jun;267(6):621-33. doi: 10.1111/j.1365-2796.2009.02198.x. Epub 2009 Nov 25. J Intern Med. 2010. PMID: 20210837 Free article.
451 results